CEO interview: Novel HDACi CS014 Brought to the Clinic

Our CEO Sten R. Sörensen comments on the recent approval for a first-in-human Phase I trial of CS014 by the EMA, in an interview with BioStock.

Tune in to hear more about this exciting news!

Watch here